Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014827 | 1.00 | MEN1 (0.31) | MEN1MAPTKMT2ACES2CES1 | |
| SCHEMBL25373049 | 0.92 | CES2 (0.43) | CES2CES1 | |
| SCHEMBL16246942 | 0.92 | CES2 (0.38) | CES2CES1 | |
| SCHEMBL16246940 | 0.92 | CES2 (0.38) | CES2CES1 | |
| SCHEMBL774760 | 0.87 | — | — | |
| SCHEMBL774759 | 0.87 | — | — | |
| SCHEMBL31352710 | 0.80 | — | — | |
| SCHEMBL31587724 | 0.79 | MAPT (0.36) | MEN1MAPTKMT2A | |
| SCHEMBL1015830 | 0.79 | MAPT (0.36) | MEN1MAPTKMT2A | |
| SCHEMBL1015828 | 0.79 | MAPT (0.36) | MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082274-A1 | Preparation of sodium-hydrogen exchanger type-1 inhibitors | LAMBERT JOHN F (US) | 2002-06-27 | — | — | US | claimed |
| WO-2023192506-A1 | MALT1 MODULATORS AND USES THEREOF | RARIFIED BIOSCIENCES, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230078513-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-07 | — | — | US | disclosed |
| EP-3765459-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Shire Human Genetic Therapies, Inc. (US) | 2021-01-20 | — | — | EP | disclosed |
| CN-112135825-A | Plasma kallikrein inhibitors and uses thereof | 夏尔人类遗传性治疗公司 | 2020-12-25 | — | — | CN | disclosed |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-10-08 | — | — | US | disclosed |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190284182-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
| WO-2019178129-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20100010219-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| EP-2103603-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | Japan Tobacco Inc. (JP) | 2009-09-23 | — | — | EP | disclosed |
| EP-1889842-A1 | HETEROCYCLIC COMPOUND | Japan Tobacco, Inc. (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20070072908-A1 | Heterocyclic compounds | JAPAN TOBACCO INC. (JP) | 2007-03-29 | — | — | US | disclosed |
| US-6753334-B2 | PREPARING A PHENYL OR QUINOLINYL HYDRAZINE BY REDUCING THE CORRESPONDING DIAZONIUM SALT WITH ASCORBIC ACID AND HEATING; COLORLESS PRODUCT; INTERMEDIATES TO DRUGS FOR REDUCING TISSUE DAMAGE FROM ISCHEMIA OR HYPOXIA | PFIZER, INC. | 2004-06-22 | — | — | US | disclosed |
| US-6627643-B2 | Sodium-hydrogen exchanger type 1 (NHE-1) inhibitors of formula I' are useful for the prevention and treatment of myocardial ischemic injury. Myocardial ischemic injury can occur in out-patient in perioperative settings and can lead to sudden | PFIZER INC. | 2003-09-30 | — | — | US | disclosed |
| US-20030119873-A1 | METHODS FOR PREPARING SODIUM-HYDROGEN EXCHANGER TYPE-1 INHIBITORS | PFIZER INC. | 2003-06-26 | — | — | US | disclosed |
| US-20020082274-A1 | Preparation of sodium-hydrogen exchanger type-1 inhibitors | LAMBERT JOHN F (US) | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | MEN1 1994/4885MAPT 4375/4885KMT2A 1860/4885 |
| US-20030119873-A1 | METHODS FOR PREPARING SODIUM-HYDROGEN EXCHANGER TYPE-1 INHIBITORS | NHERF1, SLC9A1, SLC9A2 | MEN1 393/4885MAPT 4068/4885KMT2A 2616/4885 |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | MEN1 686/4885MAPT 2953/4885KMT2A 1382/4885 |
| US-20190284182-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | MEN1 686/4885MAPT 2953/4885KMT2A 1382/4885 |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | MEN1 686/4885MAPT 2953/4885KMT2A 1382/4885 |
| US-20020082274-A1 | Preparation of sodium-hydrogen exchanger type-1 inhibitors | SLC9A1, NHERF1, SLC9A5 | MEN1 592/4885MAPT 3766/4885KMT2A 2694/4885 |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | MEN1 686/4885MAPT 2953/4885KMT2A 1382/4885 |
| US-20070072908-A1 | Heterocyclic compounds | HSD11B1, HSD11B2, CYP11B1 | MEN1 935/4885MAPT 4183/4885KMT2A 1820/4885 |
| US-20100010219-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | HSD11B1, HSD11B2, HSD17B11 | MEN1 1832/4885MAPT 3680/4885KMT2A 3033/4885 |
| US-20230078513-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | MEN1 686/4885MAPT 2953/4885KMT2A 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.